Literature DB >> 31257204

Clonal evolution in myeloma: a narrow road to remission.

Cornelius C Miething1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31257204      PMCID： PMC6601107          DOI： 10.3324/haematol.2019.220152

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  New Drugs in Multiple Myeloma.

Authors:  Chutima Kunacheewa; Robert Z Orlowski
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

2.  Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Authors:  Guy Ledergor; Assaf Weiner; Mor Zada; Shuang-Yin Wang; Yael C Cohen; Moshe E Gatt; Nimrod Snir; Hila Magen; Maya Koren-Michowitz; Katrin Herzog-Tzarfati; Hadas Keren-Shaul; Chamutal Bornstein; Ron Rotkopf; Ido Yofe; Eyal David; Venkata Yellapantula; Sigalit Kay; Moshe Salai; Dina Ben Yehuda; Arnon Nagler; Lev Shvidel; Avi Orr-Urtreger; Keren Bahar Halpern; Shalev Itzkovitz; Ola Landgren; Jesus San-Miguel; Bruno Paiva; Jonathan J Keats; Elli Papaemmanuil; Irit Avivi; Gabriel I Barbash; Amos Tanay; Ido Amit
Journal:  Nat Med       Date:  2018-12-06       Impact factor: 53.440

3.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

4.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

5.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

6.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.

Authors:  B A Walker; C P Wardell; A Brioli; E Boyle; M F Kaiser; D B Begum; N B Dahir; D C Johnson; F M Ross; F E Davies; G J Morgan
Journal:  Blood Cancer J       Date:  2014-03-14       Impact factor: 11.037

7.  Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Graham H Jackson; Faith E Davies; Charlotte Pawlyn; David A Cairns; Alina Striha; Corinne Collett; Anna Hockaday; John R Jones; Bhuvan Kishore; Mamta Garg; Cathy D Williams; Kamaraj Karunanithi; Jindriska Lindsay; Matthew W Jenner; Gordon Cook; Nigel H Russell; Martin F Kaiser; Mark T Drayson; Roger G Owen; Walter M Gregory; Gareth J Morgan
Journal:  Lancet Oncol       Date:  2018-12-14       Impact factor: 41.316

8.  Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Authors:  John R Jones; Niels Weinhold; Cody Ashby; Brian A Walker; Chris Wardell; Charlotte Pawlyn; Leo Rasche; Lorenzo Melchor; David A Cairns; Walter M Gregory; David Johnson; Dil B Begum; Sidra Ellis; Amy L Sherborne; Gordon Cook; Martin F Kaiser; Mark T Drayson; Roger G Owen; Graham H Jackson; Faith E Davies; Mel Greaves; Gareth J Morgan
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

9.  Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Authors:  Aurore Perrot; Valerie Lauwers-Cances; Jill Corre; Nelly Robillard; Cyrille Hulin; Marie-Lorraine Chretien; Thomas Dejoie; Sabrina Maheo; Anne-Marie Stoppa; Brigitte Pegourie; Lionel Karlin; Laurent Garderet; Bertrand Arnulf; Chantal Doyen; Nathalie Meuleman; Bruno Royer; Jean-Richard Eveillard; Lotfi Benboubker; Mamoun Dib; Olivier Decaux; Arnaud Jaccard; Karim Belhadj; Sabine Brechignac; Brigitte Kolb; Cecile Fohrer; Mohamad Mohty; Margaret Macro; Paul G Richardson; Victoria Carlton; Martin Moorhead; Tom Willis; Malek Faham; Kenneth C Anderson; Jean-Luc Harousseau; Xavier Leleu; Thierry Facon; Philippe Moreau; Michel Attal; Hervé Avet-Loiseau; Nikhil Munshi
Journal:  Blood       Date:  2018-09-24       Impact factor: 25.476

10.  Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Lorenzo Melchor; Sanna Hulkki; Nicola E Potter; David C Johnson; Kerry Fenwick; Iwanka Kozarewa; David Gonzalez; Christopher J Lord; Alan Ashworth; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2012-05-09       Impact factor: 22.113
View more
  2 in total

1.  LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Roni Shouval; Omer Teper; Joshua A Fein; Ivetta Danylesko; Noga Shem Tov; Ronit Yerushalmi; Abraham Avigdor; Elena Vasilev; Hila Magen; Arnon Nagler; Avichai Shimoni
Journal:  Bone Marrow Transplant       Date:  2020-02-17       Impact factor: 5.483

2.  Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine.

Authors:  Martina Zátopková; Tereza Ševčíková; Viola Fanfani; Zuzana Chyra; Lucie Říhová; Renata Bezděková; David Žihala; Kateřina Growková; Jana Filipová; Lucie Černá; Lucie Broskevičova; Fedor Kryukov; Jiří Minařík; Jana Smejkalová; Vladimír Maisnar; Ĺubica Harvanová; Luděk Pour; Alexandra Jungova; Tereza Popková; Juli Rodriguez Bago; Anjana Anilkumar Sithara; Matouš Hrdinka; Tomáš Jelínek; Michal Šimíček; Giovanni Stracquadanio; Roman Hájek
Journal:  Blood Adv       Date:  2022-01-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.